<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Most patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> do not progress to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, but those who do seem to have markedly increased survival when <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> are detected at an early stage </plain></SENT>
<SENT sid="1" pm="."><plain>Most surveillance programs are based on histological assessment of <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, but <z:mpath ids='MPATH_589'>dysplasia</z:mpath> is subject to observer variation and transient diagnoses of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> increase the cost of medical care </plain></SENT>
<SENT sid="2" pm="."><plain>We have previously validated flow cytometric increased 4N fractions and <z:mp ids='MP_0004024'>aneuploidy</z:mp> as predictors of progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>However, multiple somatic genetic lesions develop during <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, and it is likely that a panel of objective biomarkers will be required to manage the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk optimally </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We prospectively evaluated endoscopic biopsies from 325 patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, 269 of whom had one or more follow-up endoscopies, by a robust platform for loss of heterozygosity (LOH) analysis, using baseline 17p (p53) LOH as a predictor and increased 4N, <z:mp ids='MP_0004024'>aneuploidy</z:mp>, high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> as outcomes </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The prevalence of 17p (p53) LOH at baseline increased from 6% in negative for <z:mpath ids='MPATH_589'>dysplasia</z:mpath> to 57% in high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (p &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with 17p (p53) LOH had increased rates of progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (relative risk [RR] = 16, p &lt; 0.001), high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (RR = 3.6, p = 0.02), increased 4N (RR = 6.1, p &lt; 0.001), and <z:mp ids='MP_0004024'>aneuploidy</z:mp> (RR = 7.5, p &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Patients with 17p (p53) LOH are at increased risk for progression to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> as well as high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, increased 4N, and <z:mp ids='MP_0004024'>aneuploidy</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>17p (p53) LOH is a predictor of progression in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> that can be combined with a panel of other validated biomarkers for risk assessment as well as intermediate endpoints in prevention trials </plain></SENT>
</text></document>